Results 171 to 180 of about 92,046 (305)

Diagnostic Value of Rapid On‐Site Evaluation Combined With Prostate Biopsy in Prostate Cancer

The Prostate, Volume 86, Issue 5, Page 542-549, April 2026.
ABSTRACT Objective To investigate the application value of Rapid On‐Site Evaluation (ROSE) in prostate biopsy. Methods All consecutive subjects who attended our clinic to underwent magnetic resonance imaging (MRI)‐ultrasound fusion biopsy due to highly suspicious findings on MRI for prostate cancer (PCa) and met the inclusion criteria were enrolled ...
Hong Ma, Anzi Cao, Huiming Hou, Pengjie Wu, Ben Wan, Ming Liu   +5 more
wiley   +1 more source

Outcomes of sequential therapy for advanced upper tract urothelial cancer and bladder cancer. [PDF]

Sci Rep
Kanesaka M, Sazuka T, Kita Y, Fukuhara H, Takaoka N, Sugino Y, Matsushita Y, Mori K, Ieda K, Shimizu Y, Anami T, Tsuchihashi K, Kobayashi M, Tatarano S, Miyake M, Matsui Y, Kitamura H, Nishiyama H, Kimura T, Kobayashi T, Ichikawa T.   +20 more
europepmc   +1 more source

Urine‐Based Bladder Cancer Diagnostics: A Local Evaluation of Cxbladder and Review of the ANZ Landscape

Trends in Urology &Men's Health, Volume 17, Issue 2, April 2026.
ABSTRACT The high demand for cystoscopies performed for bladder cancer diagnosis or surveillance imposes a significant burden on regional centres with limited capacity. Cxbladder is a urinary biomarker test that estimates the likelihood of bladder cancer.
Claris Oh, Kim Tien Chah, Kian Lotter, Steven Lun, Manuel Yuhico   +4 more
wiley   +1 more source

Nanosecond pulsed electric fields induce cell-size-dependent selective permeabilization of urothelial cancer cells. [PDF]

Commun Biol
Kielbik A, Hellwich E, Bahlinger V, Sowa P, Lambton D, Kühs M, Barcena ML, Vakhrusheva O, Proebsting H, Walz S, Schäffer TE, Fend F, Novickij V, Amend B, Tsaur I.   +14 more
europepmc   +1 more source

Cutaneous Immune‐Related Adverse Events and Efficacy of Immune Checkpoint Inhibitors for Patients With Advanced Solid Organ Malignancies

International Journal of Dermatology, Volume 65, Issue 4, Page 790-796, April 2026.
ABSTRACT Introduction Immune checkpoint inhibitors (ICIs) have significantly improved outcomes for patients with advanced solid tumors. While low‐grade immune‐related adverse events (irAEs) are associated with prolonged survival, high‐grade irAEs have been associated with poorer survival. Cutaneous immune‐related adverse events (cirAEs) affect up to 20%
David O'Reilly, Gregg Murray, Orla M Fitzpatrick, Hebatalla Ismail, Gavin P Dowling, Gargi Roy, David Synnott, Maggie O'Connor, Bryan T Hennessy, Oscar Breathnach, Liam Grogan, Megan Greally, Adrian Murphy, Patrick G Morris, Karen Eustace, Muireann Roche, Stephen Madden, Jarushka Naidoo   +17 more
wiley   +1 more source

Beyond survival: the role of quality of life in modern urothelial cancer therapy. [PDF]

Transl Cancer Res
Yajima S, Masuda H.
europepmc   +1 more source

Enfortumab vedotin plus pembrolizumab in treatment‐naïve metastatic urothelial carcinoma patients: An Austrian real‐world analysis

International Journal of Cancer, Volume 158, Issue 6, Page 1654-1665, 15 March 2026.
What's new? New antibody‐drug conjugates (ADCs) and immunotherapies have helped expand treatment options for urothelial carcinoma (UC). Clinical trials suggest that the ADC enfortumab vedotin (EV) and the immunotherapeutic agent pembrolizumab, when used in combination, are especially effective against UC.
Dora Niedersuess‐Beke, Karl Mayrhofer, Johanna Krauter, Johannes Franke, Dominic Vais, Maximillian Pallauf, David Kiesl, Ferdinand Luger, Jacob Pfuner, Angelika Terbuch, Thomas Bauernhofer, Jasmin Spielgelberg, Andreas Banner, Stefan Aufderklamm, Clemens Wiesinger, Susanne Schnabel, Simon Peter Gampenrieder, Josef Mühlmann, Sonia Vallet, Sabine Weibrecht, Franz Stoiber, Haleh Andalibi, Harun Fajkovic, Hossein Taghizadeh, Jan Miechowiecki, Roman Taedcke, Daniel Heintel, Shahrokh F. Shariat, Martin Pichler, Wolfgang Hilbe, Renate Pichler   +30 more
wiley   +1 more source

Antibody-drug conjugates in metastatic urothelial cancer: Highway to heaven. [PDF]

World J Clin Oncol
D'Angelo A, Catalano M, De Gennaro Aquino I, Gangi V, Roviello G.   +4 more
europepmc   +1 more source

Glycosylated LGALS3BP is highly secreted by bladder cancer cells and represents a novel urinary disease biomarker

Molecular Oncology, Volume 20, Issue 3, Page 823-837, March 2026.
Urinary LGALS3BP is elevated in bladder cancer patients compared to healthy controls as detected by the 1959 antibody–based ELISA. The antibody shows enhanced reactivity to the high‐mannose glycosylated variant secreted by cancer cells treated with kifunensine (KIF).
Asia Pece, Giulio Lovato, Ilaria Cela, Arianna Mercatelli, Benedetta Ferro, Jussi Nikkola, Sara Pagotto, Tommaso Grottola, Vincenzo De Laurenzi, Rossella Cicchetti, Antonio Marchetti, Luigi Schips, Rossano Lattanzio, Stefano Iacobelli, Emily Capone, Peter Black, Mads Daugaard, Michele Marchioni, Gianluca Sala   +18 more
wiley   +1 more source

Navigating Therapeutic Landscapes in Urothelial Cancer: From Chemotherapy to Precision Immuno-Oncology. [PDF]

Cancers (Basel)
Somoto T, Utsumi T, Ikeda R, Ishitsuka N, Noro T, Suzuki Y, Iijima S, Sugizaki Y, Oka R, Endo T, Kamiya N, Suzuki H.   +11 more
europepmc   +1 more source